## Ahsan Alam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11702324/publications.pdf

Version: 2024-02-01

33 papers	966 citations	16 h-index	454955 30 g-index
33 all docs	33 docs citations	33 times ranked	1461 citing authors

#	Article	IF	CITATIONS
1	Autosomal dominant polycystic kidney disease. Lancet, The, 2019, 393, 919-935.	13.7	337
2	Decreased Survival in Liver Transplant Patients Requiring Chronic Dialysis: A Canadian Experience. Transplantation, 2008, 85, 1277-1280.	1.0	57
3	Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1573-1579.	4.5	52
4	Total Kidney Volume in Autosomal Dominant Polycystic KidneyÂDisease: A Biomarker of Disease Progression and Therapeutic Efficacy. American Journal of Kidney Diseases, 2015, 66, 564-576.	1.9	51
5	Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	1.1	45
6	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. Journal of Clinical Lipidology, 2012, 6, 303-309.	1.5	42
7	Management of ESRD in Patients With Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 164-172.	1.4	41
8	Cardiovascular Death in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 335-340.	4.5	40
9	Impact of acute kidney injury following liver transplantation on longâ€term outcomes. Clinical Transplantation, 2017, 31, e12863.	1.6	33
10	Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769578.	1.1	28
11	Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811880158.	1.1	27
12	Serum Adiponectin Levels and Mortality after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 460-467.	4.5	24
13	Hepcidin-25 in Diabetic Chronic Kidney Disease Is Predictive for Mortality and Progression to End Stage Renal Disease. PLoS ONE, 2015, 10, e0123072.	2.5	24
14	Left Ventricular Hypertrophy in ADPKD: Changing Demographics. Current Hypertension Reviews, 2013, 9, 27-31.	0.9	23
15	Health Professional–Identified Barriers to Living Donor Kidney Transplantation: A Qualitative Study. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811982838.	1.1	22
16	Serum Erythropoietin Level and Mortality in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2879-2886.	4.5	21
17	The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrology, 2015, 16, 136.	1.8	18
18	Association Between the Publication of the Initiating Dialysis Early and Late Trial and the Timing of Dialysis Initiation in Canada. JAMA Internal Medicine, 2019, 179, 934.	5.1	13

#	Article	IF	CITATIONS
19	Efficacy of Educational Interventions in Improving Measures of Living-donor Kidney Transplantation Activity: A Systematic Review and Meta-analysis. Transplantation, 2019, 103, 2566-2575.	1.0	10
20	Elevated troponin I levels but not low grade chronic inflammation is associated with cardiac-specific mortality in stable hemodialysis patients. BMC Nephrology, 2013, 14, 247.	1.8	9
21	Serial <i>versus</i> single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients. Nephrology, 2018, 23, 69-74.	1.6	9
22	Platelet reactivity in stable cardiovascular patients with chronic kidney disease. Platelets, 2018, 29, 455-462.	2.3	8
23	Knowledge Translation Interventions to Improve the Timing of Dialysis Initiation. Canadian Journal of Kidney Health and Disease, 2016, 3, 205435811666525.	1.1	7
24	Multifaceted Intervention to Increase the Use of Home Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 535-545.	4.5	5
25	Evaluating cimetidine for GFR estimation in liver transplant recipients. Nephrology Dialysis Transplantation, 2010, 25, 1285-1289.	0.7	4
26	Risk factors for progression in ADPKD. Current Opinion in Nephrology and Hypertension, 2015, 24, 290-294.	2.0	4
27	Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 32-41.	1.9	4
28	Effects of a Knowledge-Translation Intervention on Early Dialysis Initiation: A Cluster Randomized Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 1791-1800.	6.1	3
29	A Review of Multiple Myeloma Patients on Dialysis Treated with High Cutoff Hemodialysis. Blood, 2010, 116, 5002-5002.	1.4	3
30	The Impact of COVID-19 on Patients With ADPKD. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110564.	1.1	1
31	Granulocyte colonyâ€stimulating factor with or without immunosuppression reduction in neutropenic kidney transplant recipients. Clinical Transplantation, 0, , .	1.6	1
32	Counterpoint: Statins do reduce fatal events. Journal of Clinical Lipidology, 2013, 7, 225-227.	1.5	0
33	Autosomal Dominant PKD in Patients With PKD2 Mutations–AÂBenign Disorder?. American Journal of Kidney Diseases, 2017, 70, 456-457.	1.9	O